Trial in Progress: Phase 1b CROSSWALK-a Trial – Crovalimab for Acute Vaso-Occlusive Episodes in SCD

Speaker(s)

• 

  Allison W. Hsia, PhD (she/her/hers)

  Lead Clinical Scientist
  Genentech
  South San Francisco, California, United States

  Slides

First Author(s)

• PB

  Pablo Bartolucci, n/a

  Professor
  University Paris-East Créteil, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center - UMGGR, Créteil, France and University Paris-East Créteil, IMRB, Laboratory of Excellence LABEX GRex, Créteil, France, Ile-de-France, France

Author(s)

• KA

  Kenneth I. Ataga, n/a

  Plough Foundation Endowed Chair in Sickle Cell Disease at The University of Tennessee Health Science
  UTHSC Center for Sickle Cell Disease, Memphis, TN, USA, Tennessee, United States
• MC

  Michael Callaghan, n/a

  Doctor
  Division of Pediatric Heamatology/Oncology, Central Michigal University SOM, Children's hospital of Michigan, Detroit, MI, USA, Michigan, United States
• LD

  Lucia De Franceschi, n/a

  Doctor
  Department of Medicine, University of Verona and AOUI Verona, Verona, Italy, Veneto, Italy
• 

  Caterina Minniti, MD

  Professor Emerita of Medicine and Pediatrics
  Albert Einstein College of Medicine
  Bronx, New York, United States
• AA

  Ari Alexandrou, n/a

  Associate Safety Director
  Roche Products Limited, Welwyn Garden City, United Kingdom, England, United Kingdom
• DI

  Diane-Charlotte Imbs, n/a

  Clinical Pharmocology Associate Director
  Certara, Inc., Paris, France, Ile-de-France, France
• HP

  Himika Patel, n/a

  Clinical Scientist
  Genentech, Inc., South San Fransisco, CA, USA, California, United States
• AS

  Alexandre Sostelly, n/a

  Senior Director Clinical Pharmacology
  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel-Stadt, Switzerland
• JS

  Jonathan Schimmel, n/a

  Doctor
  Icahn School of Medicine at Mount Sinai, Department of Emergency Medicine, New York, NY, USA, New York, United States